Preemptive Therapy Versus Universal Prophylaxis with Ganciclovir for Cytomegalovirus in Solid Organ Transplant Recipients
Clinical Infectious Diseases2001Vol. 32(5), pp. 742–751
Citations Over TimeTop 10% of 2001 papers
Abstract
Whether preemptive therapy or universal prophylaxis with ganciclovir is the optimal approach against cytomegalovirus (CMV) remains unresolved. Controversy abounds with respect to the efficacy of preemptive therapy, the reliability of preemptive therapy tools, the logistical difficulties in conducting surveillance monitoring for CMV, the cost of prophylaxis, the effect of prophylaxis on indirect sequelae of CMV and epidemiology of CMV, and the potential for emergence of ganciclovir-resistant CMV. Although neither approach is wholly adequate, a discussion of the relative merits and limitations of the 2 approaches may guide the selection of a rational approach toward prevention of CMV infection in organ transplant recipients.
Related Papers
- → Severe Cytomegalovirus Hepatitis in a Pregnant Woman Treated with Ganciclovir(1998)31 cited
- → Correlation between CMV genotypes, multiple infections with herpesviruses (HHV-6, 7) and development of CMV disease in kidney recipients in Kuwait(2003)20 cited
- → Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients(1993)41 cited
- Improved survival with cytomegalovirus infection after intestinal transplantation in children.(1996)
- → Enhancement of Murine Cytomegalovirus Infection during Graft-vs.-Host Reaction(1977)39 cited